JW SHINYAK CORPORATION Logo

JW SHINYAK CORPORATION

Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.

067290 | KO

Overview

Corporate Details

ISIN(s):
KR7067290007
LEI:
Country:
South Korea
Address:
경기도 과천시 과천대로7길 38 -, 과천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

JW Shinyak Corporation is a pharmaceutical company that operates as a specialized maker for the clinical market. The company develops, produces, and supplies high-quality specialty medicines and medical supplies, with a primary focus on the fields of dermatology, urology, and otolaryngology. Committed to research and development, JW Shinyak aims to develop innovative new drugs through advanced medical technology, including its proprietary "DC vacuum technology" and "CTP". The company's product portfolio includes treatments for conditions such as androgenic alopecia (hair loss), endocrine disorders, and various bacterial infections.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-01 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1015.4 KB
2025-05-08 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.7 KB
2025-03-19 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.7 MB
2025-03-18 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 474.4 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 25.9 KB
2025-02-25 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.2 KB
2025-02-25 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 95.3 KB
2025-02-25 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 96.4 KB
2025-02-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.4 KB
2025-02-07 00:00
Regulatory News Service
주식등의대량보유상황보고서(일반)
Korean 74.0 KB
2025-02-07 00:00
Regulatory News Service
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.2 KB
2025-02-07 00:00
Regulatory News Service
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB

Automate Your Workflow. Get a real-time feed of all JW SHINYAK CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JW SHINYAK CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JW SHINYAK CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America
EPRX
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France
EAPI

Talk to a Data Expert

Have a question? We'll get back to you promptly.